A Phase 4, Open-Label, Single-Group Safety and Immunogenicity Study of RECOTHROM (rThrombin) in Pediatric Subjects Undergoing Synchronous Burn Wound Excision and Skin Grafting

Trial Profile

A Phase 4, Open-Label, Single-Group Safety and Immunogenicity Study of RECOTHROM (rThrombin) in Pediatric Subjects Undergoing Synchronous Burn Wound Excision and Skin Grafting

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 May 2014

At a glance

  • Drugs Thrombin alfa (Primary)
  • Indications Surgical blood loss
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ZymoGenetics
  • Most Recent Events

    • 28 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top